跳转至内容
Merck
CN

Y0001002

丁卡因 盐酸盐

European Pharmacopoeia (EP) Reference Standard

别名:

4-(丁氨基)-苯甲酸-2-(二甲氨基)乙酯, 丁卡因 盐酸盐

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C15H24N2O2 · HCl
化学文摘社编号:
分子量:
300.82
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

丁卡因 盐酸盐, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C15H24N2O2.ClH/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3;/h6-9,16H,4-5,10-12H2,1-3H3;1H

SMILES string

Cl.CCCCNc1ccc(cc1)C(=O)OCCN(C)C

InChI key

PPWHTZKZQNXVAE-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

tetracaine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

正在寻找类似产品? 访问 产品对比指南

Application

眼用局部麻醉药;用于脊髓麻醉

Biochem/physiol Actions

阻断 Ca2+ 从肌浆网的电压敏感性释放。

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Skull and crossbones

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - STOT SE 3

target_organs

Central nervous system

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Helen Giannakopoulos et al.
Journal of the American Dental Association (1939), 143(8), 872-880 (2012-08-03)
The authors evaluated the cardiovascular effects and pharmacokinetics of an intranasal 3 percent tetracaine/0.05 percent oxymetazoline spray developed to provide needle-free anesthesia of maxillary teeth. The authors administered to 12 participants a proposed maximum recommended dose (MRD) (18 milligrams tetracaine/0.3
Yue Jiang et al.
International journal of pharmaceutics, 436(1-2), 806-814 (2012-08-09)
The aggregation behavior of the cationic drug/anionic surfactant vesicles formed by tetracaine hydrochloride (TH) and double-chain surfactant, sodium bis(2-ethylhexyl)sulfosuccinate (AOT), was investigated. By controlling the molar ratio of TH to AOT, a transition from catanionic vesicles to micelles was observed.
Akihiro Tanaka et al.
Antimicrobial agents and chemotherapy, 58(8), 4380-4383 (2014-05-21)
We have reported significantly higher convulsion prevalence in patients treated with cefepime than in those treated with meropenem. Additionally, cefepime-associated convulsions were found only in patients with brain disorders, not renal failure. Here, we compared the convulsive liability of cefepime
Halima Maulidi et al.
Pediatrics, 130(6), e1704-e1707 (2012-11-07)
Infants in NICUs undergo a variety of painful procedures. The management of pain has become an integral part of newborn infant care with the use of both systemic and topical agents to provide analgesia and anesthesia for procedural pain. Tetracaine
Thomas B Marriott et al.
Clinical therapeutics, 34(10), 2174-2183 (2012-09-05)
The lidocaine/tetracaine heated patch is typically applied to the skin for 20 to 30 minutes to provide local dermal analgesia prior to venous access or minor dermatologic procedures. The potential exists for the use of multiple heated patches for longer

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持